Physician profile
William B Evans
NPI 1053420158
$5,630.03
in general payments reported to CMS, 2019-2025
36 companies · $882 in 2025
The $882 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $968 · 2020: $1,389 · 2021: $510 · 2022: $255 · 2023: $533 · 2024: $1,093 · 2025: $882.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,494 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,494.09 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,538.70 | 2019-2025 | |
| Janssen Biotech, INC. | $659.70 | 2019-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $563.09 | 2019-2025 | Xifaxan, Trulance, Uceris |
| Takeda Pharmaceuticals U.S.A., INC. | $514.93 | 2019-2024 | Eohilia |
| Celgene Corporation | $198.37 | 2022-2024 | Zeposia |
| Olympus America INC. | $182.27 | 2024-2025 | Single Use Electrosurgical Knife Kd-655, Single Use Biliary Balloon Dilator, Visiglide |
| Medtronic, INC. | $181.29 | 2023 | Gi Genius |
| Boston Scientific Corporation | $178.44 | 2021-2025 | Compliance Endokit, Orcapod, Watchman Flx |
| Cook Medical LLC | $128.35 | 2025 | Echotip Insight |
| Genzyme Corporation | $122.06 | 2022-2024 | |
| Aimmune Therapeutics, INC. | $111.35 | 2024-2025 | Zenpep |
| Ambu INC. | $107.08 | 2021 | |
| Phathom Pharmaceuticals, INC. | $99.29 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $95.39 | 2020-2025 | |
| Allergan, INC. | $91.40 | 2020 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $90.36 | 2019-2025 | |
| Amgen INC. | $90.33 | 2021-2025 | Uplizna |
| Madrigal Pharmaceuticals | $69.44 | 2025 | Rezdiffra |
| Ironwood Pharmaceuticals, INC | $64.09 | 2020-2021 | |
| Astellas Pharma US INC | $62.72 | 2024 | Xospata |
| Pfizer INC. | $57.68 | 2024-2025 | |
| Ipsen Biopharmaceuticals, INC | $50.12 | 2024-2025 | Iqirvo |
| Qol Medical, LLC | $48.55 | 2019-2020 | |
| Nestle Healthcare Nutrition INC. | $48.02 | 2022-2023 | |
| Lilly USA, LLC | $41.70 | 2024 | Omvoh |
| Micro-Tech Endoscopy USA, INC. | $38.64 | 2023 | Blue Boost |
| Ferring Pharmaceuticals INC. | $35.24 | 2020 | |
| Daiichi Sankyo INC. | $29.14 | 2021-2024 | Injectafer |
| Ardelyx, INC. | $26.11 | 2024 | Ibsrela |
| Csl Behring | $18.53 | 2020 | |
| Ucb, INC. | $16.70 | 2020 | |
| Redhill Biopharma INC. | $16.59 | 2020 | |
| Dynavax Technologies Corporation | $15.22 | 2024 | Heplisav-B |
| Conmed Corporation | $14.83 | 2021 | |
| Shire North American Group INC | $12.65 | 2019 | |
| Merck Sharp & Dohme LLC | $11.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.